Mercado de Diagnóstico Molecular da Europa, Subprodutos (Reagentes e Kits, Instrumentos e Serviços e Software), Tecnologia (Espectrometria de Massa (MS), Eletroforese Capilar, Sequenciação de Próxima Geração (NGS), Chips e Microarray, Métodos Baseados em Reação em Cadeia da Polimerase (PCR) , Citogenética, Hibridização in situ (ISH ou FISH), Imagiologia molecular e outros), Aplicação (Oncologia, Farmacogenómica, Microbiologia, Testes pré-natais, Tipagem de tecidos, Rastreio sanguíneo, Doenças cardiovasculares, Doenças neurológicas, Doenças infeciosas e outros), Utilizador final ( Hospital, Laboratórios Clínicos e Académicos), País (Alemanha, França, Espanha, Turquia, Reino Unido, Holanda, Rússia, Suíça, Bélgica, Itália e Resto da Europa) Tendências e previsões do setor até 2028 .
Análise de Mercado e Insights: Mercado de Diagnóstico Molecular na Europa
Espera-se que o mercado de diagnóstico molecular ganhe crescimento de mercado no período previsto de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 5,5% no período previsto de 2021 a 2028 e deverá atingir 13.637,22 milhões de dólares até 2028. Espera-se que o aumento da prevalência de doenças infeciosas e cancro impulsione o crescimento do mercado de diagnóstico molecular.
O diagnóstico molecular identifica ou diagnostica doenças como doenças infeciosas , doenças genéticas, doenças cardiovasculares, doenças neurológicas e outras, estudando moléculas como o ADN, ARN e proteínas num tecido ou fluido. Diferentes tecnologias como PCR, espectrometria de massa, sequenciação de segunda geração, citogenética, hibridização in situ, imagiologia molecular e outras são utilizadas para diagnosticar diferentes doenças.
Espera-se que a crescente procura de ferramentas de diagnóstico molecular para diagnosticar a COVID-19 impulsione o crescimento do mercado de diagnóstico molecular. Espera-se que o elevado custo da instrumentação atue como uma grande restrição ao crescimento do mercado de diagnóstico molecular. Espera-se que o aumento da população geriátrica atue como uma oportunidade para o crescimento do mercado de diagnóstico molecular. Espera-se que a elevada concorrência entre os participantes do mercado atue como um desafio para o crescimento do mercado de diagnóstico molecular.
O relatório de mercado de diagnóstico molecular fornece detalhes sobre a quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado nacional e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações de mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado de diagnóstico molecular, contacte a Data Bridge Market Research para obter um briefing de analista.
Âmbito e dimensão do mercado de diagnóstico molecular
O mercado de diagnóstico molecular está segmentado com base nos produtos, tecnologia, aplicação e utilizador final. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base nos produtos, o mercado de diagnóstico molecular está segmentado em reagentes e kits, instrumentos e serviços e software . Em 2021, prevê-se que o segmento de instrumentos domine o mercado de diagnóstico molecular devido ao aumento da procura de tecnologia avançada para diagnosticar doenças como doenças infeciosas, cancro e outras.
- Com base na tecnologia, o mercado de diagnóstico molecular está segmentado em espectrometria de massa (MS) , eletroforese capilar, sequenciação de última geração (NGS), chips e microarray, métodos baseados na reação em cadeia da polimerase (PCR), citogenética, hibridização in situ (ISH). ou FISH), imagens moleculares e outros. Em 2021, prevê-se que o segmento de métodos baseados na reação em cadeia da polimerase (PCR) domine o mercado de diagnóstico molecular devido ao aumento da procura de kits de PCR para diagnosticar a COVID-19 e conter a pandemia.
- Com base na aplicação, o mercado de diagnóstico molecular está segmentado em oncologia, farmacogenómica, microbiologia , testes pré-natais, tipagem de tecidos, rastreio sanguíneo, doenças cardiovasculares, doenças neurológicas, doenças infeciosas e outras. Em 2021, prevê-se que o segmento das doenças infeciosas domine o mercado do diagnóstico molecular devido ao aumento de doenças infeciosas como a gripe, COVID-19, SIDA e outras e à maior procura de tecnologia de diagnóstico molecular altamente eficiente.
- Com base no utilizador final, o mercado de diagnóstico molecular está segmentado em hospitais , laboratórios clínicos e académicos. Em 2021, prevê-se que o segmento dos laboratórios clínicos domine o mercado do diagnóstico molecular devido ao número crescente de doentes com diversas doenças e à crescente necessidade de instrumentos de diagnóstico.
Análise do mercado de diagnóstico molecular na Europa a nível dos países
O mercado europeu de diagnóstico molecular é analisado e são fornecidas informações sobre o tamanho do mercado por país, produtos, tecnologia, aplicação e utilizador final, conforme referenciado acima.
Os países abrangidos pelo relatório do mercado de diagnóstico molecular na Europa são a Alemanha, França, Espanha, Turquia, Reino Unido, Países Baixos, Rússia, Suíça, Bélgica, Itália e resto da Europa.
Prevê-se que o segmento de produtos na região da Alemanha cresça com a maior taxa de crescimento no período previsto de 2021 a 2028 devido ao aumento da procura de instrumentos de diagnóstico para diagnosticar doentes com COVID-19 e outras doenças cardiovasculares, doenças infeciosas e outras. O segmento de produtos na Bélgica está a dominar o mercado europeu de diagnóstico molecular devido ao aumento dos gastos em cuidados de saúde. O Reino Unido está a liderar o crescimento do mercado europeu de diagnóstico molecular para o segmento de risco devido à crescente procura de testes no local de atendimento e medicina de precisão.
A secção do relatório sobre os países também fornece fatores individuais que impactam o mercado e alterações na regulamentação do mercado nacional que impactam as tendências atuais e futuras do mercado. Pontos de dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e a disponibilidade de marcas europeias e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, bem como o impacto dos canais de vendas, são considerados ao fornecer uma análise de previsão dos dados do país.
O crescimento das atividades estratégicas dos principais participantes do mercado para aumentar a sensibilização para o diagnóstico molecular está a impulsionar o crescimento do mercado de diagnóstico molecular
O mercado de diagnóstico molecular também fornece análises de mercado detalhadas para cada país em crescimento no mercado de diagnóstico molecular. Além disso, fornece informações detalhadas sobre a estratégia dos participantes do mercado de diagnóstico molecular e a sua presença geográfica. Os dados estão disponíveis para o período histórico de 2010 a 2019.
Análise do cenário competitivo e da quota de mercado nos diagnósticos moleculares
O panorama competitivo do mercado de diagnóstico molecular fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produto, aprovações de produto, patentes, largura e amplitude do produto, domínio da aplicação, curva de vida da tecnologia. Os pontos de dados fornecidos acima estão apenas relacionados com o foco da empresa no mercado europeu de diagnóstico molecular.
As principais empresas que estão a lidar com o relatório do mercado de diagnóstico molecular da Europa são a Abbott, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., BD, bioMérieux SA, Cepheid, Hologic, Inc., Myriad Genetics, Inc., QIAGEN, Agilent Technologies, Inc., Quidel Corporation, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., IMMUCOR, Luminex Corporation, Meridian Bioscience, F Hoffmann-La Roche Ltd e GenMark Diagnostics, Inc., entre outros participantes nacionais. Os analistas do DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
Muitos contratos, acordos e lançamentos são também iniciados por empresas de todo o mundo, o que está também a acelerar o mercado de diagnóstico molecular.
Por exemplo,
- Em junho de 2021, a Thermo Fisher Scientific Inc. lançou um novo produto chamado Attune CytPix, um citómetro de fluxo fluorescente que oferece imagens melhoradas e foco acústico com uma câmara de alta velocidade.
A colaboração, o lançamento de produtos, a expansão de negócios, os prémios e reconhecimentos, as joint ventures e outras estratégias dos participantes do mercado estão a aumentar a presença da empresa no mercado de diagnóstico molecular, o que também traz benefícios para o crescimento dos lucros da organização.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE MOLECULAR DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PRODUCT AND BRAND ANALYSIS: EUROPE MOLECULAR DIAGNOSTICS MARKET
4.2 ROLE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN EUROPE MOLECULAR DIAGNOSTICS MARKET
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING DEMAND FOR MOLECULAR DIAGNOSTIC TOOLS TO DIAGNOSE COVID-19
5.1.2 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER
5.1.3 RISING FUNDING FOR MOLECULAR DIAGNOSIS PRODUCTS
5.1.4 RISING DEMAND FOR POINT-OF-CARE (POC) TESTING
5.1.5 DEVELOPMENT OF COMPANION DIAGNOSTIC ASSAY AND PERSONALIZED MEDICINES
5.2 RESTRAINTS
5.2.1 HIGH COST OF INSTRUMENTATIONS
5.2.2 STRINGENT LEGAL AND REGULATORY STANDARDS ARE EXPECTED TO HAMPER THE MARKET GROWTH
5.2.3 DELAY IN APPROVAL OF EXPERIMENTAL TEST FOR MOLECULAR DIAGNOSIS
5.3 OPPORTUNITIES
5.3.1 RISING GERIATRIC POPULATION
5.3.2 INCREASING ADOPTION OF ANALYSER SOFTWARE FOR MOLECULAR DIAGNOSIS
5.3.3 RISING AWARENESS REGARDING RAPID TECHNOLOGICAL ADVANCEMENTS
5.3.4 RISING HEALTHCARE EXPENDITURE IN DEVELOPING REGION
1.4 CHALLENGES
5.3.5 HIGH COMPETITION AMONG MARKET PLAYERS
5.3.6 DISTURBED SUPPLY CHAIN DUE TO COVID-19
6 IMPACT OF COVID-19 ON THE EUROPE MOLECULAR DIAGNOSTICS MARKET
6.1 ANALYSIS ON IMPACT OF COVID-19 ON THE EUROPE MOLECULAR DIAGNOSTICS MARKET
6.2 AFTERMATH OF COVID-19 AND GOVERNMENT INITIATIVES FOR GROWTH OF THE MOLECULAR DIAGNOSTICS MARKET
6.3 IMPACT ON DEMAND
6.4 IMPACT ON SUPPLY CHAIN
6.5 IMPACT ON PRICE
6.6 STRATEGIC INITIATIVES BY MANUFACTURERS
6.7 THE RISING COVID-19 CASES IS LEADING THE MOLECULAR DIAGNOSTICS MARKET
6.8 CONCLUSION
7 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 FULLY AUTOMATED INSTRUMENTS
7.2.2 SEMI-AUTOMATED INSTRUMENTS
7.3 REAGENTS AND KITS
7.4 SERVICES AND SOFTWARES
8 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
8.2.1 REAL-TIME PCR
8.2.2 DIGITAL PCR
8.2.3 REVERSE TRANSCRIPTASE PCR
8.2.4 QUANTITATIVE FLUORESCENT PCR
8.2.5 DIRECT LINEAR ANALYSIS
8.2.6 COLD PCR
8.3 NEXT GENERATION SEQUENCING (NGS)
8.4 CYTOGENETICS
8.5 CAPILLARY ELECTROPHORESIS
8.6 IN SITU HYBRIDIZATION (ISH OR FISH)
8.7 MOLECULAR IMAGING
8.7.1 OPTICAL IMAGING
8.7.2 FDG-PET
8.8 MASS SPECTROMETRY (MS)
8.9 CHIPS AND MICROARRAY
8.1 OTHERS
9 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 INFECTIOUS DISEASES
9.2.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.2.2 NEXT GENERATION SEQUENCING (NGS)
9.2.3 CYTOGENETICS
9.2.4 CAPILLARY ELECTROPHORESIS
9.2.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.2.6 MOLECULAR IMAGING
9.2.7 MASS SPECTROMETRY (MS)
9.2.8 CHIPS AND MICROARRAY
9.2.9 OTHERS
9.3 MICROBIOLOGY
9.3.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.3.2 NEXT GENERATION SEQUENCING (NGS)
9.3.3 CYTOGENETICS
9.3.4 CAPILLARY ELECTROPHORESIS
9.3.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.3.6 MOLECULAR IMAGING
9.3.7 MASS SPECTROMETRY (MS)
9.3.8 CHIPS AND MICROARRAY
9.3.9 OTHERS
9.4 BLOOD SCREENING
9.4.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.4.2 NEXT GENERATION SEQUENCING (NGS)
9.4.3 CYTOGENETICS
9.4.4 CAPILLARY ELECTROPHORESIS
9.4.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.4.6 MOLECULAR IMAGING
9.4.7 MASS SPECTROMETRY (MS)
9.4.8 CHIPS AND MICROARRAY
9.4.9 OTHERS
9.5 ONCOLOGY
9.5.1 ONCOLOGY, BY CANCER TYPE
9.5.1.1 BREAST CANCER
9.5.1.2 COLORECTAL CANCER
9.5.1.3 LUNG CANCER
9.5.1.4 PROSTATE CANCER
9.5.1.5 OTHERS
9.5.2 ONCOLOGY, BY TECHNOLOGY
9.5.2.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.5.2.2 NEXT GENERATION SEQUENCING (NGS)
9.5.2.3 CYTOGENETICS
9.5.2.4 CAPILLARY ELECTROPHORESIS
9.5.2.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.5.2.6 MOLECULAR IMAGING
9.5.2.7 MASS SPECTROMETRY (MS)
9.5.2.8 CHIPS AND MICROARRAY
9.5.2.9 OTHERS
9.6 TISSUE TYPING
9.6.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.6.2 NEXT GENERATION SEQUENCING (NGS)
9.6.3 CYTOGENETICS
9.6.4 CAPILLARY ELECTROPHORESIS
9.6.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.6.6 MOLECULAR IMAGING
9.6.7 MASS SPECTROMETRY (MS)
9.6.8 CHIPS AND MICROARRAY
9.6.9 OTHERS
9.7 PHARMACOGENOMICS
9.7.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.7.2 NEXT GENERATION SEQUENCING (NGS)
9.7.3 CYTOGENETICS
9.7.4 CAPILLARY ELECTROPHORESIS
9.7.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.7.6 MOLECULAR IMAGING
9.7.7 MASS SPECTROMETRY (MS)
9.7.8 CHIPS AND MICROARRAY
9.7.9 OTHERS
9.8 PRENATAL TESTS
9.8.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.8.2 NEXT GENERATION SEQUENCING (NGS)
9.8.3 CYTOGENETICS
9.8.4 CAPILLARY ELECTROPHORESIS
9.8.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.8.6 MOLECULAR IMAGING
9.8.7 MASS SPECTROMETRY (MS)
9.8.8 CHIPS AND MICROARRAY
9.8.9 OTHERS
9.9 NEUROLOGICAL DISEASES
9.9.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.9.2 NEXT GENERATION SEQUENCING (NGS)
9.9.3 CYTOGENETICS
9.9.4 CAPILLARY ELECTROPHORESIS
9.9.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.9.6 MOLECULAR IMAGING
9.9.7 MASS SPECTROMETRY (MS)
9.9.8 CHIPS AND MICROARRAY
9.9.9 OTHERS
9.1 CARDIOVASCULAR DISEASES
9.10.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.10.2 NEXT GENERATION SEQUENCING (NGS)
9.10.3 CYTOGENETICS
9.10.4 CAPILLARY ELECTROPHORESIS
9.10.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.10.6 MOLECULAR IMAGING
9.10.7 MASS SPECTROMETRY (MS)
9.10.8 CHIPS AND MICROARRAY
9.10.9 OTHERS
9.11 OTHERS
9.11.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.11.2 NEXT GENERATION SEQUENCING (NGS)
9.11.3 CYTOGENETICS
9.11.4 CAPILLARY ELECTROPHORESIS
9.11.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.11.6 MOLECULAR IMAGING
9.11.7 MASS SPECTROMETRY (MS)
9.11.8 CHIPS AND MICROARRAY
9.11.9 OTHERS
10 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 CLINICAL LABORATORIES
10.3 HOSPITAL
10.4 ACADEMICS
11 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 ITALY
11.1.4 RUSSIA
11.1.5 U.K.
11.1.6 SPAIN
11.1.7 TURKEY
11.1.8 SWITZERLAND
11.1.9 BELGIUM
11.1.10 NETHERLANDS
11.1.11 REST OF EUROPE
12 EUROPE MOLECULAR DIAGNOSTICS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT
14 COMPANY PROFILES
14.1 ABBOTT LABORATORIES
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 F. HOFFMANN-LA ROCHE LTD
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 ILLUMINA, INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 HOLOGIC, INC.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 BIOMÉRIEUX SA
14.5.1 COMPANY SNAPSHOT
14.5.2 COMPANY SHARE ANALYSIS
14.5.3 REVENUE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 AGILENT TECHNOLOGIES, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 BD
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 BECKMAN COULTER, INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 BIO-RAD LABORATORIES, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENTS
14.1 CEPHEID
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENTS
14.11 GENMARK DIAGNOSTICS, INC.
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 IMMUCOR
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 LIFE TECHNOLOGIES
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 LUMINEX CORPORATION
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 MERRIDIAN BIOSCIENCE
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 MYRIAD GENETICS, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENTS
14.17 QIAGEN
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 QUIDEL CORPORATION
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT
14.19 SIEMENS HEALTHCARE GMBH
14.19.1 COMPANY SNAPSHOT
14.19.2 REVENUE ANALYSIS
14.19.3 PRODUCT PORTFOLIO
14.19.4 RECENT DEVELOPMENTS
14.2 THERMO FISHER SCIENTIFIC INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Lista de Tabela
LIST OF TABLES
TABLE 1 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 2 EUROPE INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 EUROPE INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 4 EUROPE REAGENTS AND KITS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE SERVICES AND SOFTWARES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 7 EUROPE POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 EUROPE POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 9 EUROPE NEXT GENERATION SEQUENCING (NGS) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 EUROPE CYTOGENETICS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 EUROPE CAPILLARY ELECTROPHORESIS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 EUROPE INS SITU HYBRIDIZATION (ISH OR FISH) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 EUROPE MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 EUROPE MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 15 EUROPE MASS SPECTROMETRY (MS) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 EUROPE CHIPS AND MICROARRAY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 EUROPE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 19 EUROPE INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 EUROPE INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 21 EUROPE MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 EUROPE MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 23 EUROPE BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 EUROPE BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 25 EUROPE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 27 EUROPE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 28 EUROPE TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 EUROPE TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 30 EUROPE PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 EUROPE PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 32 EUROPE PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 EUROPE PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 34 EUROPE NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 EUROPE NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 36 EUROPE CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 EUROPE CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 38 EUROPE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 EUROPE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 40 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 EUROPE CLINICAL LABORATORIES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 EUROPE HOSPITAL IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 EUROPE ACADEMICS IN MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 44 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 45 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 46 EUROPE INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 47 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 48 EUROPE POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 49 EUROPE MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 50 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 51 EUROPE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 52 EUROPE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 53 EUROPE PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 54 EUROPE MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 55 EUROPE PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 56 EUROPE TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 57 EUROPE BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 58 EUROPE CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 59 EUROPE NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 60 EUROPE INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 61 EUROPE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 62 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 GERMANY MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 64 GERMANY INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 65 GERMANY MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 66 GERMANY POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 67 GERMANY MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 68 GERMANY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 69 GERMANY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 70 GERMANY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 71 GERMANY PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 72 GERMANY MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 GERMANY PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 74 GERMANY TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 75 GERMANY BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 76 GERMANY CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 77 GERMANY NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 78 GERMANY INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 79 GERMANY OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 80 GERMANY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 81 FRANCE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 82 FRANCE INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 83 FRANCE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 84 FRANCE POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 85 FRANCE MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 86 FRANCE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 87 FRANCE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 88 FRANCE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 89 FRANCE PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 90 FRANCE MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 91 FRANCE PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 92 FRANCE TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 93 FRANCE BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 94 FRANCE CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 95 FRANCE NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 96 FRANCE INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 97 FRANCE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 98 FRANCE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 ITALY MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 100 ITALY INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 101 ITALY MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 102 ITALY POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 103 ITALY MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 104 ITALY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 105 ITALY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 106 ITALY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 107 ITALY PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 108 ITALY MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 109 ITALY PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 110 ITALY TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 111 ITALY BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 112 ITALY CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 113 ITALY NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 114 ITALY INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 115 ITALY OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 116 ITALY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 117 RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 118 RUSSIA INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 119 RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 120 RUSSIA POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 121 RUSSIA MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 122 RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 123 RUSSIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 124 RUSSIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 125 RUSSIA PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 126 RUSSIA MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 127 RUSSIA PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 128 RUSSIA TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 129 RUSSIA BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 130 RUSSIA CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 131 RUSSIA NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 132 RUSSIA INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 133 RUSSIA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 134 RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 135 U.K. MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 136 U.K. INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 137 U.K. MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 138 U.K. POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 139 U.K. MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 140 U.K. MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 141 U.K. ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 142 U.K. ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 143 U.K. PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 144 U.K. MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 145 U.K. PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 146 U.K. TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 147 U.K. BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 148 U.K. CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 149 U.K. NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 150 U.K. INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 151 U.K. OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 152 U.K. MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 153 SPAIN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 154 SPAIN INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 155 SPAIN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 156 SPAIN POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 157 SPAIN MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 158 SPAIN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 159 SPAIN ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 160 SPAIN ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 161 SPAIN PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 162 SPAIN MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 163 SPAIN PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 164 SPAIN TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 165 SPAIN BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 166 SPAIN CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 167 SPAIN NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 168 SPAIN INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 169 SPAIN OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 170 SPAIN MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 171 TURKEY MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 172 TURKEY INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 173 TURKEY MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 174 TURKEY POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 175 TURKEY MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 176 TURKEY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 177 TURKEY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 178 TURKEY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 179 TURKEY PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 180 TURKEY MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 181 TURKEY PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 182 TURKEY TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 183 TURKEY BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 184 TURKEY CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 185 TURKEY NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 186 TURKEY INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 187 TURKEY OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 188 TURKEY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 189 SWITZERLAND MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 190 SWITZERLAND INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 191 SWITZERLAND MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 192 SWITZERLAND POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 193 SWITZERLAND MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 194 SWITZERLAND MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 195 SWITZERLAND ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 196 SWITZERLAND ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 197 SWITZERLAND PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 198 SWITZERLAND MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 199 SWITZERLAND PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 200 SWITZERLAND TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 201 SWITZERLAND BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 202 SWITZERLAND CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 203 SWITZERLAND NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 204 SWITZERLAND INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 205 SWITZERLAND OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 206 SWITZERLAND MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 207 BELGIUM MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 208 BELGIUM INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 209 BELGIUM MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 210 BELGIUM POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 211 BELGIUM MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 212 BELGIUM MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 213 BELGIUM ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 214 BELGIUM ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 215 BELGIUM PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 216 BELGIUM MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 217 BELGIUM PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 218 BELGIUM TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 219 BELGIUM BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 220 BELGIUM CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 221 BELGIUM NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 222 BELGIUM INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 223 BELGIUM OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 224 BELGIUM MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 225 NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 226 NETHERLANDS INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 227 NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 228 NETHERLANDS POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 229 NETHERLANDS MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 230 NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 231 NETHERLANDS ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 232 NETHERLANDS ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 233 NETHERLANDS PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 234 NETHERLANDS MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 235 NETHERLANDS PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 236 NETHERLANDS TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 237 NETHERLANDS BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 238 NETHERLANDS CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 239 NETHERLANDS NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 240 NETHERLANDS INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 241 NETHERLANDS OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 242 NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 243 REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
Lista de Figura
LIST OF FIGURES
FIGURE 1 EUROPE MOLECULAR DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 EUROPE MOLECULAR DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE MOLECULAR DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE MOLECULAR DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE MOLECULAR DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE MOLECULAR DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE MOLECULAR DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE MOLECULAR DIAGNOSTICS MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE MOLECULAR DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE MOLECULAR DIAGNOSTICS MARKET AND GROWING WITH THE HIGHEST SHARE IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 THE INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER IS EXPECTED TO DRIVE THE EUROPE MOLECULAR DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MOLECULAR DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE MOLECULAR DIAGNOSTICS MARKET
FIGURE 14 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2020
FIGURE 15 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020
FIGURE 16 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020
FIGURE 17 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020
FIGURE 18 EUROPE MOLECULAR DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 19 EUROPE MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 20 EUROPE MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 21 EUROPE MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 22 EUROPE MOLECULAR DIAGNOSTICS MARKET: BY PRODUCT (2021 & 2028)
FIGURE 23 EUROPE MOLECULAR DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
